Recommendations for the management of gastrointestinal stromal tumors;Recommandations pour la prise en charge des tumeurs stromales gastro-intestinales

Hepato-Gastro

Volumn 12, Issue 5, 2005, Pages 377-389

  Le Cesne, A ^c   Landi, B ^c   Bonvalot, S ^c   Monges, G ^c   Ray Coquard, I ^c   Duffaud, F ^c   Bui Nguyen, B ^c   Bugat, R ^c   Chayvialle, J A ^c   Rougier, P ^c   Bouche O ^c   Bonichon, F ^c   Lassau, N ^c   Vanel, D ^c   Nordlinger, B ^c   Stoeckle, E ^c   Meeus, P ^c   Coindre, J M ^c   Scoazec, J Y ^c   Emile, J F ^c   Ranchere D ^c   Blay, J Y ^a,b   more..

^a CENTRE LÉON BÉRARD   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR;

CANCER DIAGNOSIS; CANCER LOCALIZATION; FRANCE; GASTROINTESTINAL TUMOR; HUMAN; PATHOLOGICAL ANATOMY; PRACTICE GUIDELINE; PROGNOSIS; RISK FACTOR; SHORT SURVEY;

EID: 25844487766     PISSN: 12537020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (44)

1. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-19.
2. Fletcher CDM, Berman JJ, Corless CL, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of Gastrointestinal Stromal Tumors: A Consensus Approach. Hum Pathol 2002; 33: 459-65.
3. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68.
4. Plaat BE, Hollema H, Molenaar WM. Soft tissue leiomyosarcomas and malignant gastrointestinal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211-20.
5. Emory TS, Sobin LH, Lukes L. Prognosis of gastrointestinal smooth-muscle (Stromal) tumors: Dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-7.
6. Joensuu H, Roberts PJ, Sarlomo-Rikala M. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6.
7. Blay JY, Berthaud P, Perol D, Ray-Coquard I, Bui BN, Duffaud F, et al. Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. Proc Am Soc Clin Oncol 2004; (abstract 9006).
8. Demetri GD, Benjamin RS, Blanke C, Choi H, Corless C, De Matteo R, et al. Optimal management of patients with Gastrintesinal stromal tumors. Expansion and update of NCCN Clinical Practice Directives. JNCCN 2004; 2(Suppl. 1).
9. Blay JY, Bonvalot S, Casali P, Choi H, Emile JF, Gronchi A, et al. Consensus Meeting for the management of gastro intestinal stromal tumors. Ann Oncol 2005; 16: 566-78.
10. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004; 22: 4514-22.
11. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002; 117: 188-93.
12. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28: 889-94.
13. Wasag B, Debiec-Rychter M, Pauwels P, Stul M, Vranckx H, Oosterom AV, et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol 2004; 17: 889-94.
14. Kindblom LG, Meis Kindblom J, Bumming P. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal tumors (GIST): a population based study of 600 cases. Ann Oncol 2003; 13: 157.
15. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer 2005; 103: 821-9.
16. Emile JF, Lemoine A, Bienfait N, Terrier P, Azoulay D, Debuire B. Length analysis of polymerase chain reaction products: a sensitive and reliable technique for the detection of mutations in KIT exon 11 in gastrointestinal stromal tumors. Diagn Mol Pathol 2002; 11: 107-12.
17. Xiao W, Oefner PJ. Denaturing high-performance liquid chromatography: A review. Hum Mutat 2001; 17: 439-74.
18. Chak A. EUS in submucosal tumors. Gastrointest Endosc 2002; 56(4 Suppl): S43-S48.
19. Landi B, Cellier C. Tumeurs stromales gastriques: qu'apporte l'échoendoscopie à l'heure de la biologie moléculaire? Acta Endoscopica 2004; 34: 1-5.
20. Buemming P, Meis-Kindblom JM, Kindblom LG, Gustavsson B, Thakrar B, Engstrom K, et al. Is there an indication for adjuvant treatment with imatinib mesylate in patients with aggressive gastrointestinal stromal tumors (GISTs)? Proc Am Soc Clin Oncol 2003; 22: (abstr 3289).
21. Nishida T, Hirota S, Taniguchi M. Familial gastrointestinal stromal tumours with germline mutations of the KIT gene. Nat Genet 1998; 19: 323-4.
22. Van den Abbeele AD, Badawi RD, Cliche J-P. 18-FDG-PET predicts response to imatinib mesylate in patients with advanced gastrointestinal stromal tumors. Proc Am Soc Clin Oncol 2002; 21: (a403 (abstract).
23. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate. Eur J Cancer 2003; 39: 2012-20.
24. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45: 17-21.
25. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005; 32: 53-62; (Epub 2004 Sep 4).
26. Lassau N, Lamuraglia M, Leclère J, Bonvalot S, Vanel D, Robert C, et al. Doppler-Ultrasonography with perfusion software and contrast medium injection as an early evaluation tool of gastro intestinal stromal tumor treated by imatinib: Results of a prospective study. Proc Am Soc Clin Oncol 2004; 22: 9048; (abstract).
27. Lassau N, Lamuraglia M, Leclere J, Rouffiac V. Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents. J Radiol 2004; 85: 704-12.
28. Choi H, Faria S, Benjamin R, Podoloff D, Macapinlac H, Charnsangavej C. Monitoring treatment effects of STI-571 on gastrointestinal stomal tumors (GIST) with CT and PET: a quantitative analysis. RSNA 2002 Scientific Program 2002; Chicago, IL: 583.
29. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45: 357-65.
30. Choi H, Macapinlac H, Burgess M. Correlation of computerized tomography (CT) and proton emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate. Proc Am Soc Clin Oncol 2003; 22: 819.
31. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF, et al. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-8.
32. DeMatteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33: 466-77.
33. Eng-Hen NG, Pollock RE, Munsell MF. Prognostic factors influencing survival in gastro-intestinal leiomyosarcoma. Ann Surg 1992; 215: 68-77.
34. Aparicio T, Boige V, Sabourin JC, Crenn P, Ducreux M, Le Cesne A, et al. S. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004; 30: 1098-103.
35. Van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, Donato di Paola E, et al. Update of phase I study of imatinib (STI 571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38: S83-S87.
36. Bumming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engstrom K, Stierner U, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003; 89: 460-4.
37. Bonvalot S. Traitement chirurgical des GIST à l'heure du GLIVEC. Ann Chir 2005; (sous presse).
38. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992; 215: 68-77.
39. Verweij J, Casali P, Zalcberg J. Early efficacy comparison of two doses of imatinib for the treatment of advanced gastrointestinal stromal tumors: interim results of a randomized phase III trial of the EORTC STBSG, ISG and AGITG. Proc Am Soc Clin Oncol 2003; 22: 814; (abstract 3272).
40. Rankin C, von Mehren M, Blanke C, Benjamin R, Fletcher CDM, Bramwell V, et al. Continued prolongation of survival by imatinib in patients with metastatic GIST. Update of results from north american intergroup phase III study S0033. Proc Am Soc Clin Oncol 2004; (abstract 9005).
41. Bauer S, Hartmann JT, Lang H, Antoch G, Dirsch, Ebeling P, et al. Schütte Imatinib may enable complete resection in previously unresectable or metastatic GIST. Proc Am Soc Clin Oncol 2004; (abstract 9023).
42. Dileo P, Randhawa R, Vansonnenberg E, Shankar S, Desai J, Morgan, et al. Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). Proc Am Soc Clin Oncol 2004; (abstract 9013).
43. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800 mg (HD) after progression on 400 mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG. Proc Am Soc Clin Oncol 2004; (abstract 9006).
44. Gross PA. Implementing evidence-based recommendations for health care: a roundtable comparing European and American experiences. JtComm J Qual Improv 2000; 26: 547-53.